Approvals in the EU and US would be good news for CSL and its shares. That's because Goldman sees potential for garadacimab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback